Bianca van Veggel - Concepedia

Author

Bianca van Veggel

Also Known As

B. Van Veggel, B. van Veggel, B.A.M.H. van Veggel, B.V. Veggel, Bianca A M H van Veggel, Bianca A. M. H. van Veggel, Bianca A.M.H. van Veggel, Bianca Amh van Veggel, Bianca van Veggel

Publications

372

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Amsterdam UMC Location Vrije Universiteit Amsterdam University Medical Center Groningen University of Groningen Erasmus MC

About

Bianca van Veggel is an author at The Netherlands Cancer Institute specializing in pathology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	184
2	Pathology	4	4	184
3	Health Sciences	1	1	10
4	Immunology	1	1	64
5	Pharmacology	1	1	10

Bianca van Veggel

Publications

322

Citations

H-Index

Page 1

	Year	Citations
Osimertinib treatment for patients with EGFR exon 20 mutation positive non-small cell lung cancer Bianca van Veggel, Juliana F. Vilacha Madeira R Santos, Sayed M.S. Hashemi, Lung Cancer MedicineOsimertinib TreatmentPathologyBronchial NeoplasmCancer Treatment	2019	92
Afatinib and Cetuximab in Four Patients With EGFR Exon 20 Insertion–Positive Advanced NSCLC Bianca van Veggel, Adrianus J. de Langen, Sayed M.S. Hashemi, Journal of Thoracic Oncology Insertion–positive Advanced NsclcMedicineImmunologyPathologyEgfr Exon 20	2018	64
High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: Results from the phase 2 multicenter POSITION20 trial Fenneke Zwierenga, Bianca van Veggel, Lizza Hendriks, Lung Cancer	2022	60
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer Sebastian Michels, Carina Heydt, Bianca van Veggel, JCO Precision Oncology	2019	36
Quantification of extraprostatic extension in prostate cancer: different parameters correlated to biochemical recurrence after radical prostatectomy Bianca van Veggel, Inge M. van Oort, J. Alfred Witjes, Histopathology	2011	21
Crizotinib treatment for patients with EGFR mutation positive NSCLC that acquire cMET amplification after EGFR TKI therapy results in short-lived and heterogeneous responses Bianca van Veggel, Adrianus J. de Langen, Sayed M.S. Hashemi, Lung Cancer	2018	21
Exposure–Response Analysis of Osimertinib in EGFR Mutation Positive Non-Small Cell Lung Cancer Patients in a Real-Life Setting René J. Boosman, M. Jebbink, Wouter B. Veldhuis, Pharmaceutical Research Exposure–response AnalysisMedicineCancer Cell BiologyPathologyReal-life Setting	2022	18
Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC. Bianca van Veggel, Anthonie J. van der Wekken, Marthe S. Paats, Journal of Clinical Oncology PathologyOncologyMetronomic TherapyClinical TrialsEgfrex20ins Positive Nsclc	2021	10

Page 1